EU Rejects Obesity Drug Qsiva for the Second TimeEU Rejects Obesity Drug Qsiva for the Second Time
Despite an appeal by Vivus, the European Medicines Agency has rejected the obesity treatment phentermine/topiramate extended release for the second time. Any benefit "does not outweigh the risks," says the EMA. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Adipex | Diabetes | Eating Disorders & Weight Management | Endocrinology | European Medicines Agency (EMA) | Health | Obesity | Phentermine | Topamax